Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma

The anti-programmed cell death protein-1 (PD-1) immune checkpoint inhibitor nivolumab is currently approved for the treatment of patients with metastatic renal cell carcinoma (mRCC); approximately 25% of patients respond. We hypothesized that we could identify a biomarker of response using radiomics to train a machine learning classifier to predict nivolumab response outcomes.Patients with mRCC of different histologies treated with nivolumab in...